Mean HbA1c 8.39 8.38 8.53 8.53 (%) -0.74 -0.38 -0.77 0.11 Baseline LS mean change from baseline Patients 28.3 12.0 35.6 5.2 (%) achieving HbA1c < 7.0% Mean change 53.62 57.65 24.87 24.11 in basal -5.62 -1.93 -1.39 -0.11 insulin dose (U) Baseline LS mean change from baseline Mean body 87.39 89.11 65.99 65.60 weight -1.80 -0.52 -0.38 0.06 (kg) Baseline LS mean change from baseline *Performed in Asian population The mean decrease in fasting plasma glucose obtained with lixisenatide treatment ranged from 0.42 mmol/L to 1.19 mmol/L at the end of the main 24-week treatment period in placebo- controlled studies.
Mean HbA1c (%) Baseline LS mean change from baseline 8.39 -0.74 8.38 -0.38 8.53 -0.77 8.53 0.11 Patients (%) achieving HbA1c < 7.0% 28.3 12.0 35.6 5.2 Mean change in basal insulin dose (U) Baseline LS mean change from baseline 53.62 -5.62 57.65 -1.93 24.87 -1.39 24.11 -0.11 Mean body weight (kg) Baseline LS mean change from baseline 87.39 -1.80 89.11 -0.52 65.99 -0.38 65.60 0.06 *Performed in Asian population The mean decrease in fasting plasma glucose obtained with lixisenatide treatment ranged from 0.42 mmol/L to 1.19 mmol/L at the end of the main 24-week treatment period in studies. controlled placebo-
auspar-lixisenatide-130820-pi.docx